LINK Healthcare receives marketing approval for DermaScar®

by / Monday, 01 September 2014 / Published in News

LINK Healthcare receives marketing approval for DermaScar®

 DermaScar® (polysiloxane) is a scar reduction gel for the treatment of keloid and hypertrophic scarring.

 Link’s newly formed Pharmacy Division expects more specialist products to follow

Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 1st September 2014


Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) announced today that it has received Australian marketing approval for DermaScar® (polysiloxane) scar reduction gel 15mg.

Mr. John Bacon, Chairman of LINK Healthcare said: “DermaScar® is a great addition to our newly created Pharmacy Team. It adds to our growing range of niche OTC products.”

About DermaScar®

DermaScar – Scar Reduction Gel (with the ingredient Polysiloxane) is for improving keloid and hypertrophic scars. It is found to improve hydration to the scar, protect the scar from infection and repel the cells that promote scar growth. It can be used as soon as the skin has healed and can improve scars up to two years old. DermaScar® will be available at all major Australian Pharmacies without a prescription (RRP $14.95).


About LINK Healthcare (Australia, New Zealand, Southern Africa, Singapore, Hong Kong & Japan)

LINK Healthcare is a privately owned specialist pharmaceutical and medical technologies business. LINK’s mission is to strive for excellence in the marketing of vitally important and unique range of specialists products that enhance the well-being of people throughout the regions of Australia, New Zealand, Asia and Southern Africa.

LINK provides exceptional regulatory, sales, marketing, customer service and supply chain infrastructure and is partnered with major blue chip pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio of ‘medicine that matters.’

LINK Healthcare has an extensive range of prescription pharmaceuticals in essential therapeutic areas including Allergy, Anaphylaxis, Analgesia/Anaesthesia, Anti-infective, Anti-retroviral, Cardiology, Endocrinology, ENT, Gastroenterology, Intensive care, Metabolic disease, Neurology, Oncology, Orphan Drugs, Palliative care, Psychiatry, Radiography, Transplantation and Toxicology.
In Australia and Southern Africa the group also commercialize a unique range of medical technology products focused in the specialist areas of advanced wound care, diabetes and point of care testing.

For more information about LINK Healthcare visit

Contact LINK Healthcare on 61 (2) 8401 9777
Corporate and Media Enquiries:
Mr John Bacon
Executive Chairman